Anavex Life Sciences Corp (AVXL)

[jimmy667]

So many have fallen under the spell unreasonable fears' doubt, uncertainty and doom as company the has been doing everything right and it's drug has performed so far better than than the company "Anavex Life Sciences" had even expected. Now the market cap has been traded down nearly low as for the entire company than Heptares R&D upfront payment of $125 Mil license agreement for "selective musicanaric" angonists the most advanced of which is in Ph1b.

From Heptares website:

Pipeline Deals

Allergan

Global R&D and commercialisation agreement (2016) under which Allergan licenses exclusive global rights to Heptares’ broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological diseases, including Alzheimer’s disease. Heptares received $125 million upfront, and is eligible for milestone payments of up to approximately $3.25 billion, plus up to double-digit royalties.

Allergan is also committing up to $50 million to joint R&D programme aimed at advancing multiple candidates through Phase 2 studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.

Here is the pipeline Allegan licenced, again from Heptares website:
Heptares Targets

GPCR Target Indication
Status Partner


Muscarinic M1 Cognitive impairment in Alzheimers, Schizophrenia, other
First-in-class selective muscarinic M1 receptor agonists in Phase 1b clinical development


Muscarinic M4 Psychosis in Schizophrenia, Alzheimer’s and other diseases
First-in-class selective M4 agonists in preclinical development


Dual M1/M4 Psychosis and cognitive impairment in Alzheimer’s, Schizophrenia and other diseases
First-in-class dual M1/M4 agonists in preclinical development

Many "real" experts in the field as Dr Harald Hempel have stated AVXL'sA2-73 is the most exciting development they have seen in AlZ. Heptares lead compound is in Ph1b.

So many people are buying into Adam F's typical BS and twisted facts and ignore solid facts of the value of Anavex Life Sciences Pipeline, which is quite evident in the Allergan/Heptares licensing deal.

McMagyar is being ultra-conservative in his analysis of the great value of Anavex to a potential BP R&D Licensing partner. This conversation of "AVXL will never make it, will dilute etc.", ad nauseam, is becoming annoyingly innane.

McMagyar, I will see you at the top along with the others who can seem to comprehend the potential value of Anavex Life Sciences.
EOM.